Assessment of the feed additive consisting of L‐cysteine hydrochloride monohydrate (2b920) for cats and dogs for the renewal of its authorisation (PRINOVA BENELUX AND FRANCE N.V) Authors: EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Roberto Edoardo Villa, Giovanna Azimonti, Eleftherios Bonos, Henrik Christensen, Mojca Durjava, Birgit Dusemund, Ronette Gehring, Boet Glandorf, Maryline Kouba, Marta López‐Alonso, Francesca Marcon, Carlo Nebbia, Alena Pechová, Miguel Prieto‐Maradona, Ilen Röhe, Katerina Theodoridou, Montserrat Anguita Freixa, Matteo L. Innocenti, Fabiola Pizzo, Jordi Tarrés‐Call Published: 2025 ABSTRACT AbstractFollowing a request from the European Commission, EFSA was asked to deliver a scientific opinion (safety and efficacy) on the application for the renewal of the authorisation of the of L‐cysteine hydrochloride monohydrate (2b920) as flavouring compound for cats and dogs. The applicant has provided evidence that the additive currently in the market complies with the existing conditions of authorisation. The additive L‐cysteine hydrochloride monohydrate remains safe for cats and dogs under the current conditions of the authorisation. Regarding user safety, the additive should be considered as irritant to skin, eyes and mucous membranes. Any exposure is considered a risk. There is no need to assess the efficacy of the additive in the context of the renewal of the authorisation. INTRODUCTION Background and Terms of Reference Regulation (EC) No 1831/2003 1 establishes the rules governing the Community authorisation of additives for use in animal nutrition. In particular, Article 14(1) of that Regulation lays down that an application for renewal shall be sent to the Commission at the latest 1 year before the expiry date of the authorisation. The European Commission received a request from Prinova Benelux and France N.V. 2 for the renewal of the authorisation of the additive consisting of L‐cysteine hydrochloride monohydrate (2b920), when used as a feed additive for cats and dogs (category: sensory additives; functional group: flavouring compounds). According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the application to the European Food Safety Authority (EFSA) as an application under Article 14(1) (renewal of the authorisation). The dossier was received on 08 January 2025 and the general information and supporting documentation are available at https://open.efsa.europa.eu/questions/EFSA‐Q‐2025‐00008. The particulars and documents in support of the application were considered valid by EFSA as of 12 February 2025. According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and documents submitted by the applicant, shall undertake an assessment in order to determine whether the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the safety for the target animals, consumer, user and the environment and on the efficacy of the feed additive consisting of L‐cysteine hydrochloride monohydrate (2b920), when used under the proposed conditions of use (see Section 3.1.1 ). Additional information L‐Cysteine hydrochloride monohydrate (2b920) is currently authorised for cats and dogs. 3 The EFSA Panel on additives and products or substances used in animal feed (FEEDAP Panel) issued an opinion on the safety of this additive for pets (2013), and other scientific opinions on the safety and efficacy of L‐cysteine hydrochloride monohydrate produced by fermentation when used as amino acid for all animal species. 4 DATA AND METHODOLOGIES Data The present assessment is based on data submitted by the applicant in the form of a technical dossier 5 in support of the authorisation request for the use of L‐cysteine hydrochloride monohydrate (2b920) as a feed additive. In accordance with Article 38 of the Regulation (EC) No 178/2002 6 and taking into account the protection of confidential information and of personal data in accordance with Articles 39 to 39e of the same Regulation, and of the Decision of EFSA's Executive Director laying down practical arrangements concerning transparency and confidentiality, 7 a non‐confidential version of the dossier has been published on Open.EFSA. According to Article 32c(2) of Regulation (EC) No 178/2002 and to the Decision of EFSA's Executive Director laying down the practical arrangements on pre‐submission phase and public consultations, EFSA carried out a public consultation on the non‐confidential version of the technical dossier from 11 March to 1 April 2025 for which no comments were received. The confidential version of the technical dossier was subject to a target consultation of the interested Member States from 17th February 2025 to 17th May 2025 for which the received comments were considered for the assessment. The FEEDAP Panel used the data provided by the applicant together with data from other sources, such as previous risk assessments by EFSA to deliver the present output. The European Union Reference Laboratory (EURL) considered that the conclusions and recommendations reached in the previous assessment regarding the methods used for the control of the L‐cysteine hydrochloride monohydrate (2b920) in animal feed are valid and applicable for the current application. 8 Methodologies The approach followed by the FEEDAP Panel to assess the safety and the efficacy of L‐cysteine hydrochloride monohydrate (2b920) is in line with the principles laid down in Regulation (EC) No 429/2008 9 and the relevant guidance documents: Guidance on the assessment of the safety of feed additives for the target species (2017), Guidance on the renewal of the authorisation of feed additives (EFSA FEEDAP Panel, 2021) and Guidance on the assessment of the safety of feed additives for the users (2023). ASSESSMENT The additive L‐cysteine hydrochloride monohydrate is currently authorised as sensory additive (functional group: flavouring compounds) for dogs and cats. This assessment regards the renewal of its authorisation. Characterisation The additive L‐cysteine hydrochloride monohydrate is identified by the Chemical Abstracts Service (CAS) number 7048‐4‐6. It has a FLAVIS No 17.032. The IUPAC name is (2R)‐2‐amino‐3‐sulfanylpropanoic acid;hydrate;hydrochloride. The molecular formula is C3H7NO2S.HCl·H2O and its molecular weight is 175.64 Da. L‐Cysteine hydrochloride monohydrate is currently authorised in solid form, produced by hydrolysis of keratin from avian feathers and with a purity of minimum 98.5%. Some modifications were introduced in the manufacturing process since the original authorisation (e.g. change in the ■■■■■ used ■■■■■; ■■■■■), which do not affect the composition of the additive. To support this, analytical data of five batches were submitted. The data provided by the applicant on the batch‐to‐batch variation, 10 impurities, microbial contamination 11 and physical properties 12 of the additive are reported in Table 1. TABLE 1Data on the batch‐to‐batch variation, impurities, microbial contamination and physical properties of L‐cysteine hydrochloride monohydrate. The data presented are average values, (range) and [number of batches analysed] for batch‐to‐batch variation, and ranges for all other parameters.ParameterSpecificationAnalysisAverageRange# Batches Batch‐to‐batch variation Cysteine HCl on DM (%) 1 ≥ 98.5%99.999.95Chloride (%)20.120.15Residue on ignition (%)0.040.03–0.045Loss on drying (%)10.210.2–10.35 Specific optical rotation (°) 2 +5.5° to +7.0°6.16.0–6.25 Impurities Lead (mg/kg)< 0.053Mercury (mg/kg)0.0065–0.00733Cadmium (mg/kg)< 0.0053Arsenic (mg/kg)< 0.0053 Dioxins and furans (upper bound 3 ) PCDD/Fs (ng WHO2005‐TEQ/kg)0.0683PCDD/Fs + PCBs (ng WHO2005‐TEQ/kg)0.103–0.1043nDL‐PCBs (μg/kg)0.744–0.7493 Mycotoxins Aflatoxins (B1 + B2 + G1 + G2) (μg/kg)< 53Fumonisin Total (μg/kg)< 303Ochratoxin A (μg/kg)< 53T‐2 toxin (μg/kg)< 13HT‐2 toxin (μg/kg)< 103Deoxynivalenol (μg/kg)< 103Zearalenone (μg/kg)< 53 Pesticides screening (mg/kg) < LOQ 4 3 Microbial contamination Salmonella spp. (per 25 g)Not detected3 Enterobacteriaceae (per 100 g)Not detected3Yeast (CFU/g)< 103Moulds (CFU/g)< 103 Physical properties Physical formSolid3Bulk density (kg/m3)827–8543Solubility (g/L at 20°C)1100Dusting potential (Stauber Heubach) (mg/m3)3.8–7.53 Note: <: below the LOQ.Abbreviations: CFU, colony forming unit; DM, dry matter. 1 Specifications set in Commission implementing Regulation (EU) 2015/2306. 2 Specifications set in Pharmacopoeia Europea 11th Edition (2023). 3 Upper bound concentrations are calculated on the assumption that all values of the different congeners below the limit of quantification are equal to the limit of quantification. TEQ = toxic equivalency factors for PCDD/Fs and dioxin‐like PCBs established by WHO in 2005 (Van den Berg et al., 2006). 4 The limit of quantification (LOQ) of the analytical method ranged 0.01 to 0.05 mg/kg depending on the pesticide considered. Data on the batch‐to‐batch variation, impurities, microbial contamination and physical properties of L‐cysteine hydrochloride monohydrate. The data presented are average values, (range) and [number of batches analysed] for batch‐to‐batch variation, and ranges for all other parameters. Note: <: below the LOQ. Abbreviations: CFU, colony forming unit; DM, dry matter. Specifications set in Commission implementing Regulation (EU) 2015/2306. Specifications set in Pharmacopoeia Europea 11th Edition (2023). Upper bound concentrations are calculated on the assumption that all values of the different congeners below the limit of quantification are equal to the limit of quantification. TEQ = toxic equivalency factors for PCDD/Fs and dioxin‐like PCBs established by WHO in 2005 (Van den Berg et al., 2006). The limit of quantification (LOQ) of the analytical method ranged 0.01 to 0.05 mg/kg depending on the pesticide considered. The data provided showed compliance with the specifications set in the authorising regulation for L‐cysteine hydrochloride monohydrate. The FEEDAP Panel considers that the microbial contamination and the amounts of the detected impurities do not raise safety concerns. Conditions of use The additive is currently authorised without a minimum or maximum content for use in complete feed for cats and dogs. 13 Under ‘Other provisions’ of the authorisation, 14 it is specified that: Indicate in the directions for use of the additive and premixture: ○the storage conditions;○supplementation with L‐cysteine hydrochloride monohydrate shall depend on the requirements of cats and dogs for sulfur‐containing amino acids and the level of other sulfur‐containing amino acids in the ration. For safety: breathing protection, safety glasses and gloves shall be worn during handling. Indicate in the directions for use of the additive and premixture: ○the storage conditions;○supplementation with L‐cysteine hydrochloride monohydrate shall depend on the requirements of cats and dogs for sulfur‐containing amino acids and the level of other sulfur‐containing amino acids in the ration. Indicate in the directions for use of the additive and premixture: ○the storage conditions;○supplementation with L‐cysteine hydrochloride monohydrate shall depend on the requirements of cats and dogs for sulfur‐containing amino acids and the level of other sulfur‐containing amino acids in the ration. ○the storage conditions; the storage conditions; ○supplementation with L‐cysteine hydrochloride monohydrate shall depend on the requirements of cats and dogs for sulfur‐containing amino acids and the level of other sulfur‐containing amino acids in the ration. supplementation with L‐cysteine hydrochloride monohydrate shall depend on the requirements of cats and dogs for sulfur‐containing amino acids and the level of other sulfur‐containing amino acids in the ration. For safety: breathing protection, safety glasses and gloves shall be worn during handling. For safety: breathing protection, safety glasses and gloves shall be worn during handling. The applicant did not request any change in the current conditions of authorisation. Safety In the previous opinion (EFSA FEEDAP Panel, 2013), the Panel concluded that the addition of L‐cysteine to the food of cats and dogs is safe provided that the balance between cysteine and methionine in the complete diet is maintained. In the absence of data, the Panel considered the additive as irritant to skin and eyes and as a potential skin sensitiser. The applicant declared that no adverse effects including incidents for target animals and/or the users have been reported since the authorisation of the additive. 15 The applicant performed a literature search to provide evidence that the additive remains safe under the authorised conditions for the target species and users. 16 The literature search was conducted using the following databases: European Chemicals Agency, US Centers for Disease Control and prevention, US Environmental Protection Agency, Food Science and Technology Abstracts® and CAB Abstracts®. No hits reporting adverse effects of L‐cysteine hydrochloride monohydrate on target species or users were retrieved. Considering the above and the fact that the composition of the additive has not been modified, the Panel considers that the additive remains safe for the target species under the current conditions of the authorisation. With regards to safety for the user, the applicant did not provide any new information. Based on the dusting potential (Section 3.1) exposure of users by inhalation is likely. Based on the safety data sheet provided, the additive should be considered as irritant to skin, eyes and mucous membranes. Conclusions of the safety The FEEDAP Panel concludes that the additive L‐cysteine hydrochloride monohydrate remains safe for cats and dogs under the current conditions of the authorisation. The additive should be considered as irritant to skin, eyes and mucous membranes. Any exposure is considered a risk. Efficacy The present application for renewal of the authorisation does not include a proposal for amending or supplementing the conditions of the original authorisation that would have an impact on the efficacy of the additive. Therefore, there is no need for assessing the efficacy of the additive in the context of the renewal of the authorisation. Post‐market monitoring The FEEDAP Panel considers that there is no need for specific requirements for a post‐market monitoring plan other than those established in the Feed Hygiene Regulation 17 and Good Manufacturing Practice. CONCLUSIONS The applicant has provided evidence that the additive currently in the market complies with the existing conditions of authorisation. The additive L‐cysteine hydrochloride monohydrate remains safe for cats and dogs under the current conditions of the authorisation. Regarding user safety, the additive should be considered as irritant to skin, eyes and mucous membranes. Any exposure is considered a risk. There is no need to assess the efficacy of the additive in the context of the renewal of the authorisation. ABBREVIATIONS Chemical Abstracts Service colony forming unit dry matter European Union Reference Laboratory EFSA Scientific Panel on Additives and Products or Substances used in Animal Feed The EU Flavour Information System International Union of Pure and Applied Chemistry limit of quantification toxic equivalency factors for dioxins, furans and dioxin‐like PCBs REQUESTOR European Commission QUESTION NUMBER EFSA‐Q‐2025‐00008 COPYRIGHT FOR NON‐EFSA CONTENT EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source. PANEL MEMBERS Roberto Edoardo Villa, Giovanna Azimonti, Eleftherios Bonos, Henrik Christensen, Mojca Durjava, Birgit Dusemund, Ronette Gehring, Boet Glandorf, Maryline Kouba, Marta López‐Alonso, Francesca Marcon, Carlo Nebbia, Alena Pechová, Miguel Prieto‐Maradona, Ilen Röhe and Katerina Theodoridou. LEGAL NOTICE Relevant information or parts of this scientific output have been blackened in accordance with the confidentiality requests formulated by the applicant pending a decision thereon by EFSA. The full output has been shared with the European Commission, EU Member States (if applicable) and the applicant. The blackening may be subject to review once the decision on the confidentiality requests is adopted by EFSA and in case it rejects some of the confidentiality requests.